A comparison of urinary biomarkers of tobacco and carcinogen exposure in smokers

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 10, 2004, Pages 1617-1623

  Murphy, Sharon E ^a,b   Link, Carrie A ^a   Jensen, Joni ^a   Le, Chap ^a   Puumala, Susan S ^a   Hecht, Stephen S ^a   Carmella, Steven G ^a   Losey, London ^a   Hatsukami, Dorothy K ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 HYDROXYPYRENE; 3' HYDROXYCOTININE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; ALKALOID; ANATABINE; BIOLOGICAL MARKER; CARCINOGEN; COTININE; GLUCURONIDE; NICOTINE; POLYCYCLIC AROMATIC HYDROCARBON; TOXIN; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EXPOSURE; HUMAN; HUMAN EXPERIMENT; METABOLITE; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; SMOKING; TOBACCO; URINE LEVEL;

ADULT; ALKALOIDS; BIOLOGICAL MARKERS; CARCINOGENS; ENDPOINT DETERMINATION; ENVIRONMENTAL EXPOSURE; FEMALE; GANGLIONIC STIMULANTS; HUMANS; MALE; NICOTINE; NITROSAMINES; POLYCYCLIC HYDROCARBONS, AROMATIC; PYRIDINES; REPRODUCIBILITY OF RESULTS; SMOKING; SMOKING CESSATION; URINALYSIS;

EID: 4944266005     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. IARC. Tobacco smoke and involuntary smoking. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon (France): IARC; 2003.
3. Hecht SS. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 2002;3:461-9.
4. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-210.
5. Hatsukami DK, Henningfeld JE, Kotlyar M. Harm reduction approaches to reducing tobacco-related mortality. Annu Rev Public Health 2004;25:1-19.
6. Institute of Medicine. Clearing the smoke. Assessing the science base for tobacco harm reduction. Washington (DC): National Academy Press; 2001.
7. Benowitz NL. Smoking less as a treatment goal for those who cannot stop smoking. Am J Med 2004;116:203-5.
8. Hecht SS, Murphy SE, Carmella SG, et al. Effects of reduced cigarette smoking on uptake of a tobacco-specific lung carcinogen. J Natl Cancer Inst 2004;96:107-15.
9. Hecht SS, Carmella SG, Le K-A, et al. Effects of reduced cigarette smoking on levels of 1-hydroxypyrene in urine. Cancer Epidemiol Biomarkers Prev 2004;13:834-42.
10. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 1998;11:559-603.
11. Upadhyaya P, Kenney PMJ, Hochalter JB, Wang M, Hecht SS. Tumorigenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) enantiomers and metabolites in the A/J mouse. Carcinogenesis 1999;20:1577-82.
12. Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002;23:907-22.
13. Jongeneelen FJ. Benchmark guideline for urinary 1-hydroxypyrene as biomarker of occupational exposure to polycyclic aromatic hydrocarbons. Ann Occup Hyg 2001;45:3-13.
14. Jacob J, Seidel A. Biomonitoring of polycyclic aromatic hydrocarbons in human urine. J Chromatogr B Analyt Technol Biomed Life Sci 2002;778:31-47.
15. Lee PN. Uses and abuses of cotinine as a marker of tobacco smoke exposure. In: Gorrod JW, Jacob P III, editors. Analytical determination of nicotine and related compounds and their metabolites. Amsterdam: Elsevier Science; 1999. p. 669-719.
16. Nakajima M, Yamamoto T, Nunoya K, et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996;24:1212-7.
17. Yamazaki H, Inoue K, Hashimoto M, Shimada T. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol 1999;73:65-70.
18. Gorrod JW, Schepers G. Biotransformation of nicotine in mammalian systems. In: Gorrod JW, Jacob P III, editors. Analytical determination of nicotine and related compounds and their metabolites. Amsterdam: Elsevier Science; 1999. p. 45-67.
19. Davis RA, Curvall M. Determination of nicotine and its metabolites in biological fluids: in vivo studies. In: Gorrod JW, Jacob P III, editors. Analytical determination of nicotine and related compounds and their metabolites. Amsterdam: Elsevier Science; 1999. p. 583-643.
20. Benowitz NL, Jacob P III, Fong I, Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 1994;268:296-303.
21. Jacob P III, Hatsukami D, Severson H, Hall S, Yu L, Benowitz NL. Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev 2002;11:1668-73.
22. Jacob P III, Yu L, Shulgin AT, Benowitz NL. Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. Am J Public Health 1999;89: 731-6.
23. Schmeltz I, Hoffmann D. Nitrogen containing compounds in tobacco and tobacco smoke. Chem Rev 1977;77:295-311.
24. Beckett AH, Sheikh AH. Proceedings: in vitro metabolic N-oxidation of the minor tobacco alkaloids, (-)methylanabasine and (-)anabasine to yield a hydroxylamine and a nitrone in lung and liver homogenates. J Pharm Pharmacol 1973;25 Suppl:171P.
25. Wiley JC, Chien DHT, Nungesser NA, Lin D, Hecht SS. Synthesis of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 4-(carbethoxynitrosamino)-1-(3- pyridyl)-1-butanone, and N′-nitrosonornicotine labeled with tritium in the pyridine ring. J Label Compd Radiopharm 1988; 25:707-16.
26. Bracher F, Papke T. Total syntheses and antimicrobial activities of pyridine alkaloids from Rubiaceae. Monatsh Chem 1995;126:805-9.
27. Jacob P III, Yu L, Liang G, Shulgin AT, Benowitz NL. Gas Chromatographic mass spectrometric method for determination of anabasine, anatabine and other tobacco alkaloids in urine of smokers and smokeless tobacco users. J Chromatogr B Biomed Appl 1993; 619:49-61.
28. Hecht SS, Hochalter JB, Villalta PW, Murphy SE. 2′-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor. Proc Natl Acad Sci 2000; 97:12493-7.
29. Hecht SS, Carmella SG, Chen M, et al. Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Res 1999;59:590-6.
30. Hecht SS, Carmella SG, Murphy SE. Effects of watercress consumption on urinary metabolites of nicotine in smokers. Cancer Epidemiol Biomarkers Prev 1999;8:907-13.
31. Carmella SG, Akerkar S, Richie JP Jr, Hecht SS. Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers' urine. Cancer Epidemiol Biomarkers Prev 1995;4:635-42.
32. Carmella SG, Le K, Hecht SS. Improved method for determination of 1-hydroxypyrene in human urine. Cancer Epidemiol Biomarkers Prev 2004;13:1261-4.
33. Kuehl GE, Murphy SE. N-glucuronidation of trans-3′-hydroxycotinine by human liver microsomes. Chem Res Toxicol 2003;16:1502-6.
34. Hatsukami DK, Lemmonds C, Zhang Y, et al. Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products. J Natl Cancer Inst 2004;96:844-52.
35. Vainio H, Weiderpass E. Smokeless tobacco: harm reduction or nicotine overload? Eur J Cancer Prev 2003;12:89-92.
36. McDonald SP, Maguire GP, Hoy WE. Validation of self-reported cigarette smoking in a remote Australian aboriginal community. Aust N Z J Public Health 2003;27:57-60.
37. Coultas DB, Stidley CA, Samet JM. Cigarette yields of tar and nicotine and markers of exposure to tobacco smoke. Am Rev Respir Dis 1993;148:435-40.
38. Benowitz NL, Jacob P III. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 1994;56:483-93.
39. Benowitz NL, Jacob P III. Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther 1984;35:499-504.
40. Swan GE, Habina K, Means B, Jobe JB, Esposito JL. Saliva cotinine and recent smoking-evidence for a nonlinear relationship. Public Health Rep 1993;108:779-83.
41. National Cancer Institute. Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. Smoking and Tobacco Control Monograph no. 13. NIH Pub. No. 99-4645. Bethesda (MD): U.S. Department of Health and Human Services, NIH, National Cancer Institute; 2001.
42. Kuehl GE, Murphy SE. N-glucuronidation of nicotine and cotinine by human liver microsomes and heterologously-expressed UDP-glucuronosyltransferases. Drug Metab Dispos 2003;31:1361-8.